Table 1. Clinicopathological, molecular and biological features of included patients stratified by Streptococcus gallolyticus infection.
| Total patients (n = 190) |
n (%) of positive SG6 (3.2) | n (%) of negative SG184 (96.8) | *p-value |
|---|---|---|---|
| Gender | 0.09 | ||
| Male | 5 (2.6) | 90 (47.4) | |
| Female | 1 (0.5) | 94 (49.5) | |
| Age (mean ± SD) | 67.6 (8.38) | 70.1 (11.4) | 0.43 |
| Type of tissue (n = 380) | 0.03 | ||
| Normal | 0 (0) | 190 (50) | |
| Tumoral | 6 (1.6) | 184 (48.4) | |
| Tumour location | 0.63 | ||
| Proximal | 2 (1.3) | 36 (23.1) | |
| Distal | 4 (2.6) | 114 (73.1) | |
| Tumour stage | 0.12 | ||
| II | 4 (4.4) | 38 (42.2) | |
| III | 1 (1.1) | 47 (52.2) | |
| CIMP status | 0.61 | ||
| Positive | 2 (1.1) | 40 (21.4) | |
| Negative | 4 (2.1) | 141 (75.4) | |
| Microsatellite phenotype | 0.42 | ||
| MSI | 0 (0) | 18 (9.5) | |
| MSS | 6 (3.2) | 166 (87.4) | |
| Molecular carcinogenetic pathways | 0.45 | ||
| CIN | 4 (2.1) | 133 (71.1) | |
| CIMP | 2 (1.1) | 30 (16) | |
| MSI | 0 (0) | 18 (9.6) | |
| CMV infection (n = 380) | 0.72 | ||
| Positive | 1 (0.3) | 44 (11.8) | |
| Negative | 5 (1.3) | 324 (86.6) | |
| EBV infection (n = 380) | 0.01 | ||
| Positive | 5 (1.3) | 127 (34) | |
| Negative | 1 (0.3) | 241 (64.4) |
SG: Streptococcus gallolyticus; SD: Standard deviation; CIMP: CpG island methylator phenotype (CIMP)-positive tumor; MSI: Microsatellite instability; MSS: Microsatellite stability; CIN: Chromosomal instability; CMV: Cytomegalovirus; EBV: Epstein-Barr virus.
*P-values are from χ2 test (Fisher's exact test if necessary) or Mann-Whitney U test comparing S. gallolyticus results with categorical or continuous variables respectively.